289,800 Shares in Pfizer Inc. $PFE Bought by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the first quarter, Holdings Channel reports. The fund bought 289,800 shares of the biopharmaceutical company’s stock, valued at approximately $8,138,000.

Several other hedge funds also recently added to or reduced their stakes in PFE. Vermillion Wealth Management Inc. grew its holdings in Pfizer by 19.4% during the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 382 shares during the period. Triad Wealth Partners LLC grew its stake in shares of Pfizer by 1.9% during the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 386 shares during the period. Eagle Capital Management LLC grew its stake in shares of Pfizer by 0.3% during the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 390 shares during the period. ETF Store Inc. increased its holdings in shares of Pfizer by 3.8% during the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares in the last quarter. Finally, Mattern Wealth Management LLC lifted its stake in shares of Pfizer by 4.6% in the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 400 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

NYSE:PFE opened at $23.64 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a market capitalization of $134.71 billion, a PE ratio of 18.04 and a beta of 0.34. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The company has a fifty day moving average of $26.00 and a two-hundred day moving average of $26.30.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the previous year, the company earned $0.92 earnings per share. The company’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.3%. Pfizer’s dividend payout ratio is presently 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded Ibrance for frontline maintenance use in HR-positive, HER2-positive advanced or metastatic breast cancer, giving Pfizer a new label expansion that could support sales and help offset pressure from older drugs. FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
• Positive Sentiment: Pfizer announced its quarterly dividend remains at $0.43 per share, reinforcing the company’s shareholder-return profile and highlighting management’s commitment to its payout. Pfizer Declares Third-Quarter 2026 Dividend
• Positive Sentiment: Pfizer was dismissed from a U.S. states’ generic drug price-fixing lawsuit, removing a potential legal overhang. Pfizer dismissed from US states’ drug price-fixing lawsuit
• Neutral Sentiment: Pfizer Ventures helped lead a $62 million Series B for Oblenio Bio, showing continued investment in early-stage biotech opportunities, though the deal is unlikely to move the stock near term. Oblenio Bio Closes $62 Million Series B
• Negative Sentiment: Earlier reports said Pfizer’s Phase 3 lung cancer data for sigvotatug vedotin failed to show a statistically significant overall survival benefit, fueling concerns about its long-term oncology pipeline and helping explain the recent weakness in PFE. Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative
• Negative Sentiment: Comparison pieces weighing AbbVie versus Pfizer and Lilly versus Pfizer suggest investors still see Pfizer as the slower-growth big pharma name relative to peers, which can keep valuation pressure on the stock. AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Bank of America lowered their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research report on Tuesday. Morgan Stanley increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. CICC Research started coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target for the company. Finally, UBS Group reaffirmed a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.